GLP-1 medicines are increasingly discussed as weight-loss injections, but their clinical significance now extends well beyond the number on a scale. Treatments containing semaglutide have established roles in type 2 diabetes and obesity, while evidence has expanded their use in selected patients at risk of cardiovascular and kidney complications. The important distinction is that benefits depend on the individual medicine, dose, diagnosis and approved indication—not simply membership in the GLP-1 drug class. What are GLP-1 medicines? Glucagon-like peptide-1 (GLP-1) is a hormone involved in blood-sugar regulation and appetite signalling. GLP-1 receptor agonists mimic some of its effects: they help the body release insulin when glucose is elevated, reduce inappropriate glucagon secretion and slow stomach emptying. Certain medicines also influence appetite and satiety, supporting weight reduction when combined with dietary changes and physical activity. Semaglutide is one example, marketed in different formulations and under different brand names for different purposes. It is a mistake to assume that products containing the same active ingredient are interchangeable. Their authorised indications, doses and administration instructions can differ, and treatment should follow the specific product label and a clinician’s assessment. Why cardiovascular protection matters Obesity and type 2 diabetes frequently coexist with hypertension, abnormal cholesterol levels and cardiovascular disease. For some patients, treatment decisions therefore involve more than lowering blood glucose or achieving weight loss. In March 2024, the US Food and Drug Administration approved Wegovy, a semaglutide product, to reduce the risk of cardiovascular death, heart attack and stroke in adults with established cardiovascular disease who also have overweight or obesity. That approval reflected evidence for a defined patient population, not a recommendation that everyone seeking weight loss should take semaglutide to prevent heart disease. Cardiovascular risk still requires attention to smoking, blood pressure, lipid management, nutrition, exercise and other proven preventive care. A developing role in kidney disease The clinical picture widened again in January 2025, when the FDA approved an additional indication for Ozempic to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This development is important because chronic kidney disease can progress silently, and diabetes is a major contributor to kidney damage worldwide. However, kidney protection does not mean GLP-1 medicines replace other appropriate therapies. Clinicians still consider blood-pressure management, kidney function monitoring, and established treatments such as renin–angiotensin system blockers or SGLT2 inhibitors where indicated. Treatment combinations and priorities must be tailored to the individual. What patients need to know about safety The most frequently reported adverse effects of semaglutide are gastrointestinal, including nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These problems may be more noticeable during dose escalation. Persistent vomiting or poor fluid intake can contribute to dehydration and kidney injury, making medical review important when symptoms are severe. Prescribing information also warns about pancreatitis, gallbladder disease and serious allergic reactions. Low blood sugar is a particular concern when semaglutide is combined with insulin or medicines that stimulate insulin release. Patients with diabetes-related eye disease may require additional monitoring. People should tell their care teams about GLP-1 treatment before procedures involving anaesthesia or deep sedation because delayed stomach emptying may affect aspiration risk. US semaglutide labels carry a boxed warning related to thyroid C-cell tumours observed in rodents. Whether this finding predicts medullary thyroid cancer in humans remains unknown. Certain semaglutide products must not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Pregnancy planning also requires discussion with a prescribing professional. Better prescribing starts with better questions Before initiating treatment, patients and clinicians should review the actual treatment goal, medical history, existing medicines, affordability, follow-up capacity and potential adverse effects. They should also distinguish between approved medicines and products sold through unverified channels. Dose changes, switching between products or stopping therapy without medical guidance can undermine safety and continuity of care. The growing evidence around GLP-1 treatment represents an important change in modern medicine: some therapies can address interconnected metabolic, cardiovascular and kidney risks. But responsible use requires precision. The right medicine for the right patient, alongside long-term preventive care, matters more than the popularity of any one drug. Medical note: This article is for general information and does not replace individual medical advice. Approved uses and product labels vary by country.